Patent: 11,090,333
✉ Email this page to a colleague
Summary for Patent: 11,090,333
| Title: | Immune stimulatory function and anti-tumor activity of TGF-β primed myeloid derived suppressor cells (MDSC) |
| Abstract: | Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-β1, and in specific embodiments the exposure to TGF-β1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity. |
| Inventor(s): | Andrew SIKORA, Padmini JAYARAMAN, Falguni PARIKH, Robin Parihar |
| Assignee: | Baylor College of Medicine |
| Application Number: | US15/759,717 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,090,333
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | SIMPONI | golimumab | Injection | 125289 | 24-Apr-09 | ⤷ Start Trial | 2036-09-14 |
| Janssen Biotech, Inc. | SIMPONI | golimumab | Injection | 125289 | 15-May-13 | ⤷ Start Trial | 2036-09-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 11,090,333
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2019046569 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017048822 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
